Dage Pharma Asia Pacific newly appointed.

DrDirk Hoenemann is the Asia Pacific Head of Medical Affairs and Early Clinical Development, where Dirk is responsible for building the company's medical functions, structure sands and workflows and developing clinical development strategies for the company's many early stage projects and small molecule compoundsDirk has led several clinical projects for more than 20 years in clinical research, translational medicine research, and the academic and pharmaceutical industries, including the first application of new antibody forms in patients with hematomas and solid tumorsin addition, he played a key role in the first CAR-T study (for LewisY antigens) launched in AustraliaDirk has been an executive in the biopharmaceutical industry several times, and during his tenure at Newbase, Dirk led early clinical development projects in the Asia Pacific region and successfully promoted the listing of nadoamine, pomadomine and asonuclein in the region"AtG-010's treatment for patients with regenerative, refractively diffuse large B-cell lymphoma has been successfully launched in the United States, and we have welcomed the exciting news of Dirk's addition to Dege, whose deep work in global translational medicine research and clinical development will add firepower to the rapid development of the team."Dirk is a very successful oncologist who has impressed us with his leadership in the face of great responsibility for his medical workI believe he will play a vital role in the expansion of de chi's Asia-Pacific landscape, to achieve our mission of 'Doctors Without Borders, Innovation and Sustainableness', and ultimately bring new hope to cancer patients in the Asia-Pacific region", said DrMei Jianming, founder and chief executive officer of Deqi PharmaDrdirk Hoenemann,, said: "I am delighted to be part of Dege Pharmaceuticals, a biopharmaceutical company focused on cutting-edge innovative drug development, and I am deeply responsible as the company's head of medical affairs and early clinical developmenthope to use their own experience and strength to promote the company's strong product pipeline clinical progress to meet the Asia-Pacific and global patient treatment needs."Dirk holds a Ph.Din medicine from the Charit Hospital affiliated with the University of Berlin and a Ph.Din internal medicine from the University of Wuerzburg .